Skip to main content
Erschienen in: Obesity Surgery 7/2010

01.07.2010 | Clinical Research

Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis

verfasst von: Fabiola Rabelo, Claudia P. M. S. Oliveira, Joel Faintuch, Daniel F. C. Mazo, Vicencia M. R. Lima, Jose Tadeu Stefano, Hermes V. Barbeiro, Francisco G. Soriano, Venancio A. Ferreira Alves, Flair J. Carrilho

Erschienen in: Obesity Surgery | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Fatty liver disease is a problem in both bariatric patients and in patients with moderate obesity. Tumor necrosis factor (TNF)-α has been frequently measured in nonalcoholic steatohepatitis (NASH) with or without diabetes, but less is known about interleukin (IL)-6 and IL-10.

Methods

Moderately obese patients (n = 80) with histologically proven steatosis (n = 29) and NASH (n = 51) were recruited. Serum levels of cytokines were documented along with clinical information. The aim was to identify the correlates of such biomolecules in a stable population.

Results

Diabetes tended to be more associated with NASH (52.5% instead of 41.4%, P = 0.015), with no difference of age, gender, or body mass index regarding steatosis. For the entire population, cytokine changes were not significant, including TNF-α and IL-6. In diabetics only, all markers tended to diminish with NASH, especially IL-10 (P = 0.000). IL-10 correlated with homeostatic model assessment index (P = 0.000) and other variables of glucose homeostasis in diabetes, thus representing a major marker of the disease.

Conclusions

(1) Generally inconsistent changes in pro- and anti-inflammatory cytokines occurred when NASH was globally compared to steatosis. (2) In contrast, downregulation of IL-6 and IL-10 was perceived in diabetics with NASH. (3) Arterial hypertension did not play a role in these circumstances. (4) IL-10 maintained strong correlations with glucose metabolism indices. (5) TNF-α could not be incriminated for progressive liver damage, as values failed to increase in NASH. (6) Investigations of IL-10 and other counterregulatory cytokines are lacking in this context and deserve further studies.
Literatur
1.
Zurück zum Zitat Mummadi RR, Kasturi KS, Chennareddyqari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–402.CrossRefPubMed Mummadi RR, Kasturi KS, Chennareddyqari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–402.CrossRefPubMed
2.
Zurück zum Zitat Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–40.CrossRefPubMed Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–40.CrossRefPubMed
3.
Zurück zum Zitat Dogru T, Ercin CN, Erdem G, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:3217–8.PubMed Dogru T, Ercin CN, Erdem G, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:3217–8.PubMed
4.
Zurück zum Zitat Wieckowska A, Papouchado B, ZhenZheng L, et al. Increased hepatic and circulating interleukin 6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–9.CrossRefPubMed Wieckowska A, Papouchado B, ZhenZheng L, et al. Increased hepatic and circulating interleukin 6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–9.CrossRefPubMed
5.
Zurück zum Zitat Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430–7.CrossRefPubMed Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430–7.CrossRefPubMed
6.
Zurück zum Zitat Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549–53.PubMed Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549–53.PubMed
7.
Zurück zum Zitat Gruady SM, Hansen B, Smith Jr SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551–6.CrossRef Gruady SM, Hansen B, Smith Jr SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551–6.CrossRef
8.
Zurück zum Zitat Kleiner DE, Brunt EM, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
9.
Zurück zum Zitat Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26:39–45.CrossRefPubMed Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26:39–45.CrossRefPubMed
10.
Zurück zum Zitat Naveau S, Balian A, Capron F, et al. Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. Gastroenterol Clin Biol. 2005;29:269–74.CrossRefPubMed Naveau S, Balian A, Capron F, et al. Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. Gastroenterol Clin Biol. 2005;29:269–74.CrossRefPubMed
11.
Zurück zum Zitat Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and atherosclerosis. Am J Gastroenterol. 2008;103:1959–65.CrossRefPubMed Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and atherosclerosis. Am J Gastroenterol. 2008;103:1959–65.CrossRefPubMed
12.
Zurück zum Zitat Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.PubMedCrossRef Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.PubMedCrossRef
13.
Zurück zum Zitat Isaacs A. Interferon as a factor of recovery from vírus infection. Proc R Soc Med. 1962;55:725–6.PubMed Isaacs A. Interferon as a factor of recovery from vírus infection. Proc R Soc Med. 1962;55:725–6.PubMed
14.
Zurück zum Zitat Salgado W, Cunha FQ, Santos JS, et al. Early identification of infectious complications in bariatric surgery by the determination of peritoneal and systemic cytokines. Obes Surg. 2009;19:867–72.PubMed Salgado W, Cunha FQ, Santos JS, et al. Early identification of infectious complications in bariatric surgery by the determination of peritoneal and systemic cytokines. Obes Surg. 2009;19:867–72.PubMed
15.
Zurück zum Zitat Tarantino G, Marra M, Contaldo F, et al. Basal metabolic rate in morbidly obese patients with nonalcoholic fatty liver disease. Clin Invest Med. 2008;31(1):E24–9.PubMed Tarantino G, Marra M, Contaldo F, et al. Basal metabolic rate in morbidly obese patients with nonalcoholic fatty liver disease. Clin Invest Med. 2008;31(1):E24–9.PubMed
16.
Zurück zum Zitat Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1946–52.CrossRefPubMed Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1946–52.CrossRefPubMed
17.
Zurück zum Zitat Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008;2:196–201.CrossRefPubMed Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008;2:196–201.CrossRefPubMed
18.
Zurück zum Zitat Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17:1696–701.CrossRef Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17:1696–701.CrossRef
19.
Zurück zum Zitat Rosenson RS. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan—effects on oxidized non-esterified free fatty acids and cytokine production. Cardiovasc Drugs Ther. 2009;23:289–94.CrossRefPubMed Rosenson RS. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan—effects on oxidized non-esterified free fatty acids and cytokine production. Cardiovasc Drugs Ther. 2009;23:289–94.CrossRefPubMed
20.
Zurück zum Zitat Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-recative protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of severity of fibrosis in NASH. J Gastroenterol. 2007;42:573–82.CrossRefPubMed Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-recative protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of severity of fibrosis in NASH. J Gastroenterol. 2007;42:573–82.CrossRefPubMed
21.
Zurück zum Zitat Peng XD, Dai LL, Huang CQ, et al. Relationship between anti-fibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis. Biochem Biophys Res Commun. 2009;388:31–4.CrossRefPubMed Peng XD, Dai LL, Huang CQ, et al. Relationship between anti-fibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis. Biochem Biophys Res Commun. 2009;388:31–4.CrossRefPubMed
22.
Zurück zum Zitat de Lalla C, Galli G, Aldrighetti L. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol. 2004;173:1417–25.PubMed de Lalla C, Galli G, Aldrighetti L. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol. 2004;173:1417–25.PubMed
23.
Zurück zum Zitat Hong EG, Ko HJ, Cho YR, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58:2525–35.CrossRefPubMed Hong EG, Ko HJ, Cho YR, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58:2525–35.CrossRefPubMed
24.
Zurück zum Zitat Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of non-alcogholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol. 2006;208:74–81.CrossRefPubMed Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of non-alcogholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol. 2006;208:74–81.CrossRefPubMed
25.
Zurück zum Zitat Estep JM, Baranova A, Hossain N, et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009;19:617–24.CrossRefPubMed Estep JM, Baranova A, Hossain N, et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009;19:617–24.CrossRefPubMed
26.
Zurück zum Zitat Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–74.CrossRefPubMed Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–74.CrossRefPubMed
27.
28.
Zurück zum Zitat Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.CrossRefPubMed Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.CrossRefPubMed
29.
Zurück zum Zitat Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in nonalcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res. 2009;42:958–62.CrossRefPubMed Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in nonalcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res. 2009;42:958–62.CrossRefPubMed
Metadaten
Titel
Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis
verfasst von
Fabiola Rabelo
Claudia P. M. S. Oliveira
Joel Faintuch
Daniel F. C. Mazo
Vicencia M. R. Lima
Jose Tadeu Stefano
Hermes V. Barbeiro
Francisco G. Soriano
Venancio A. Ferreira Alves
Flair J. Carrilho
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 7/2010
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-010-0181-4

Weitere Artikel der Ausgabe 7/2010

Obesity Surgery 7/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.